- Sponsor: American Diabetes Association (ADA)
- Internal Deadline: May 26, 2017
- Sponsor Deadline: July 3, 2017
- Link: http://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE
The Pathway to Stop Diabetes Research Program intends to attract brilliant scientists at the peak of their creativity to diabetes research, and to accelerate their research progress by providing the necessary resources and support for conducting transformative science. This program will consider applications directed toward all topics relevant to prevention, treatment and cure of all types of diabetes (type 1, type 2, and gestational diabetes), diabetes-related disease states (obesity, pre-diabetes, and other insulin resistant states) and the complications of diabetes. The program intends to attract a broad range of expertise to diabetes research from various fields of science and technology, including medicine, biology, chemistry, engineering, mathematics, and physics.
The three prestigious Pathway awards are available by institutional nomination only:
- Initiator Award (INI)
- Description: This two-phased award is designed to support the transition of scientists from mentored training to independent research faculty.
- Eligibility: Eligible applicants must currently be in research training positions (post-doctoral fellow, research fellowship) and have no more than seven years of research training following terminal doctoral degree. Applicants cannot concurrently hold an NIH K99/R00 grant. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.
- Support: Awards provide two distinct phases of research support: Phase 1 provides up to two years of support for mentored training at a maximum of $100,000 per year (including 10% indirect costs), Phase 2 provides up to five years of support for independent research at a maximum of $325,000 per year (including 30% indirect costs). Maximum combined support for Phase 1 and Phase 2 is $1,625,000.
- Accelerator Award (ACE)
- Description: This award is designed to support exceptional, independent early-career researchers who have distinguished themselves as promising investigators and are in the beginning stages of establishing successful, sustainable diabetes research programs.
- Eligibility: Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for, or received, an R01/U01 renewal or a second R01/U01 award. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.
- Support: Awards provide five years of research support at a maximum of $325,000 per year (including 30% indirect costs), for a total of $1,625,000.
- Visionary Award (VSN)
- Description: Awards are designed to support established, experienced investigators with strong records of outstanding productivity in fields outside of diabetes who are interested in applying their considerable skills and expertise to diabetes research. These awards are highly competitive and intended to support particularly innovative and transformational ideas that have the potential to have an exceptional impact in diabetes.
- Eligibility: Applicants must hold independent faculty positions and have demonstrated significant productivity in their current field of research. Applicants cannot have previously received national grant support (NIH, NIDDK, ADA, JDRF, etc.), as either a PI or Co-PI, in diabetes or diabetes-related research.
- Support: Awards provide two distinct phases of research support: Phase 1 provides up to three years of support at a maximum of $325,000 per year (including 30% indirect costs), Phase 2 provides up to two years of support at a maximum of $325,000 per year (including 30% indirect costs). Phase 2 is contingent upon demonstration of significant contributions to the field of diabetes research in Phase 1. Maximum combined support for Phase 1 and Phase 2 is $1,625,000.
Please read the full program announcement before preparing your internal application.
Each institution is allowed a maximum of one nomination per grant cycle. The nomination can be for any one of the Pathway Program Award types: Initiator, Accelerator, OR Visionary. If you are interested in submitting for this program, you must submit an internal application to email@example.com according to the required instructions below.
Internal Applications must include the following:
- A cover page listing
- The name of this funding opportunity and title of your proposal
- The type of award for which you are applying (Initiator, Accelerator, or Visionary)
- Your name, UGA position, home department, email, and UGA contact information
- Collaborator names, positions, and institutions (if any)
- A (maximum four-page) Research Strategy that addresses the following:
- Scientific question(s)/specific problem(s) to be addressed
- Specific approach(es) that will be employed
- Significance and potential impact of the work
- The potential risks and challenges, and how they will be overcome
- One paragraph describing why this proposal should be UGA’s submission (i.e., why it will be the most competitive for this program)
- PI’s curriculum vitae
Internal Submission Instructions
The above internal application materials should be submitted via email as a single .PDF file to firstname.lastname@example.org by the internal deadline listed above.
Please submit questions regarding the internal competition to Lauren Sisko at email@example.com.
For questions directly related to this program, please contact the ADA at 1 (800) 342-2383 or firstname.lastname@example.org.
View our calendar for all Current and Closed Limited Submissions.
Subscribe to our listerv to receive weekly internal competition announcements.